Shots:

• The approval is based on the P-III head-to-head OPTIMUM trial involves assessing Ponvory (20 mg) vs Teriflunomide (14 mg) in adults with relapsing MS and follows >10 yrs of cumulative data demonstrating its efficacy and safety
• The results demonstrated superior efficacy in reducing annual relapses by 30.5%- no confirmed relapses (30.5% vs 61%)- reducing the number of new GdE T1 lesions and the number of new or enlarging T2 lesions by 59% and 56%- confirmed disability progression
• Ponvory (ponesimod) is a selective S1P1 modulator to treat adults with relapsing MS and is the 1^st and only FDA-approved oral disease modifying therapy studied against an established oral comparator

 ­ Ref: PRNewswire | Image: Janssen